{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["101(5)"],"submitter":["Boquoi A"],"funding":["Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts"],"pubmed_abstract":["Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) can be late complications following mutagenic treatment. Limited data is available on the outcome of patients developing therapy-related MDS and AML after treatment for multiple myeloma (MM). We identified 250 patients with therapy-associated MDS or AML in the Duesseldorf MDS registry. Of those, 50 patients were previously diagnosed with multiple myeloma (mm-MDS/AML). We compared them to patients with de novo MDS (n = 4862) and to patients with MDS following other underlying diseases (tMDS) (n = 200). mm-MDS patients and tMDS patients showed similar karyotypes and degrees of cytopenia. However, mm-MDS patients had significantly higher blast counts and more often belonged to the high-risk group according to the International P"],"journal":["Annals of hematology"],"pagination":["1031-1038"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8993729"],"repository":["biostudies-literature"],"pubmed_title":["Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis."],"pmcid":["PMC8993729"],"pubmed_authors":["Mohring A","Savickaite I","Boquoi A","Hildebrandt B","Gattermann N","Kobbe G","Schroeder T","Fenk R","Banahan SM","Strapatsas J","Haas R","Germing U"],"additional_accession":[]},"is_claimable":false,"name":"Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.","description":"Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) can be late complications following mutagenic treatment. Limited data is available on the outcome of patients developing therapy-related MDS and AML after treatment for multiple myeloma (MM). We identified 250 patients with therapy-associated MDS or AML in the Duesseldorf MDS registry. Of those, 50 patients were previously diagnosed with multiple myeloma (mm-MDS/AML). We compared them to patients with de novo MDS (n = 4862) and to patients with MDS following other underlying diseases (tMDS) (n = 200). mm-MDS patients and tMDS patients showed similar karyotypes and degrees of cytopenia. However, mm-MDS patients had significantly higher blast counts and more often belonged to the high-risk group according to the International P","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-04T08:24:22.311Z","creation":"2025-04-04T08:24:22.311Z"},"accession":"S-EPMC8993729","cross_references":{"pubmed":["35262868"],"doi":["10.1007/s00277-022-04775-1"]}}